| --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------|-------|-------| | | | | | Not started | | | | Medtronic plc Q1 FY25 Earnings presentation Work in progress Update complete Not started Work in progress Update complete | | | | August 20th, 2024 | | | Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are ...

Exhibit 99.1 NEWS RELEASE Contacts: | --- | --- | |------------------|--------------------| | Erika Winkels | Ryan Weispfenning | | Public Relations | Investor Relations | | +1-763-526-8478 | +1-763-505-4626 | FOR IMMEDIATE RELEASE Medtronic reports first quarter fiscal 2025 financial results Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain Stimulation, and Deep Brain ...

Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain Stimulation, and Deep Brain StimulationGALWAY, Ireland, Aug. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced financial results for its first quarter (Q1) of fiscal year 2025 (FY25), which ended July 26, 2024.Key HighlightsRevenue of $7.9 billion, adjusted revenue of $8.0 billion, increased 2.8% as repo ...

Medtronic plc (MDT) is scheduled to report first-quarter fiscal 2025 results on Aug 20, before the opening bell.In the last reported quarter, the company’s adjusted earnings of $1.46 exceeded the Zacks Consensus Estimate by 0.69%. Medtronic beat estimates in each of the trailing four quarters, the average surprise being 4.48%.The Zacks Consensus Estimate for fiscal first-quarter revenues is pegged at $7.90 billion, suggesting growth of 2.5% year over year. The consensus estimate for first-quarter earnings i ...

JHVEPhoto Medtronic (NYSE:MDT) continues to tread water as the broader market advances. The stock is up just 4% over the past 12 months, significantly underperforming the iShares U.S. Medical Devices ETF (IHI) which is higher by 10%. The Health Care Sector ETF (XLV) has returned better than 15% while the S&P 500 has beaten them all with a 28% performance from year-ago levels. I reiterate a buy rating on MDT, though. I see the stock as still undervalued today ahead of its Q1 2025 earnings report due out ...

JHVEPhotoInvestment thesis My initial bullish thesis about Medtronic (NYSE:MDT) aged somewhat good as the stock delivered a total 1.9% return since mid-February. As I underlined in my initial thesis, MDT is a good option for investors seeking low-volatility stock with solid dividend growth. The company reports its fiscal Q1 earnings soon, on August 20. Today I want to update my thesis and explain why I believe there are robust reasons to remain moderately bullish about MDT. Moreover, the valuation still ...

The office building of Medtronic Inc., an American medical technology company, is being pictured in ... [+] Shanghai, China, on July 23, 2024. (Photo by Costfoto/NurPhoto via Getty Images)NurPhoto via Getty ImagesMedtronic (NYSE: MDT) is scheduled to report its fiscal 2025 first-quarter results on Tuesday, August 20 (fiscal year ends in April). We expect Medtronic stock to trade higher post-Q1 results announcement, with its revenues and earnings expected to be slightly above the street estimates. The compan ...

GALWAY, Ireland, Aug. 16, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 15, 2024, approved the company's cash dividend for the second quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividen ...

Medtronic (MDT) recently announced two major developments within its diabetes care business. The company received FDA approval for its Simplera continuous glucose monitor (CGM), which marks a significant step forward in diabetes management.Along with the FDA approval, Medtronic announced a global partnership with another MedTech stalwart, Abbott (ABT) . Considering the fact that the global diabetes care market has shown remarkable growth over the past few years, this partnership is expected to be strategica ...

In its upcoming report, Medtronic (MDT) is predicted by Wall Street analysts to post quarterly earnings of $1.20 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $7.9 billion, representing a year-over-year increase of 2.5%.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company reveals its earni ...